NO20022502L - Nye antidiabetiske midler - Google Patents

Nye antidiabetiske midler

Info

Publication number
NO20022502L
NO20022502L NO20022502A NO20022502A NO20022502L NO 20022502 L NO20022502 L NO 20022502L NO 20022502 A NO20022502 A NO 20022502A NO 20022502 A NO20022502 A NO 20022502A NO 20022502 L NO20022502 L NO 20022502L
Authority
NO
Norway
Prior art keywords
antidiabetic agents
new antidiabetic
new
agents
antidiabetic
Prior art date
Application number
NO20022502A
Other languages
English (en)
Norwegian (no)
Other versions
NO20022502D0 (no
Inventor
David Michael Evans
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of NO20022502L publication Critical patent/NO20022502L/no
Publication of NO20022502D0 publication Critical patent/NO20022502D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
NO20022502A 1999-11-30 2002-05-27 Nye antidiabetiske midler NO20022502D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9928330.1A GB9928330D0 (en) 1999-11-30 1999-11-30 Novel antidiabetic agents
PCT/GB2000/004572 WO2001040180A2 (en) 1999-11-30 2000-11-30 N-substituted 2-cyanopyrrolidines and their use as antidiabetic agents

Publications (2)

Publication Number Publication Date
NO20022502L true NO20022502L (no) 2002-05-27
NO20022502D0 NO20022502D0 (no) 2002-05-27

Family

ID=10865461

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20022502A NO20022502D0 (no) 1999-11-30 2002-05-27 Nye antidiabetiske midler

Country Status (23)

Country Link
US (2) US6911467B2 (ko)
EP (1) EP1351932A2 (ko)
JP (1) JP2003515585A (ko)
KR (1) KR20020063185A (ko)
CN (1) CN1192020C (ko)
AU (1) AU781060B2 (ko)
BR (1) BR0015788A (ko)
CA (1) CA2392713A1 (ko)
CZ (1) CZ20021520A3 (ko)
EE (1) EE200200273A (ko)
GB (1) GB9928330D0 (ko)
HR (1) HRP20020421B1 (ko)
HU (1) HUP0203700A3 (ko)
IL (2) IL149359A0 (ko)
MX (1) MXPA02005253A (ko)
MY (1) MY131036A (ko)
NO (1) NO20022502D0 (ko)
PL (1) PL355333A1 (ko)
RU (1) RU2265012C2 (ko)
SK (1) SK7212002A3 (ko)
UA (1) UA75341C2 (ko)
WO (1) WO2001040180A2 (ko)
ZA (1) ZA200204283B (ko)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0109146D0 (en) * 2001-04-11 2001-05-30 Ferring Bv Treatment of type 2 diabetes
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
WO2003000180A2 (en) * 2001-06-20 2003-01-03 Merck & Co., Inc. Dipeptidyl peptidase inhibitors for the treatment of diabetes
ATE374181T1 (de) 2001-06-27 2007-10-15 Smithkline Beecham Corp Fluorpyrrolidine als dipeptidylpeptidaseinhibitoren
ATE370943T1 (de) 2001-06-27 2007-09-15 Smithkline Beecham Corp Fluoropyrrolidine als dipeptidyl-peptidase inhibitoren
EP1399420B1 (en) * 2001-06-27 2007-12-05 SmithKline Beecham Corporation Pyrrolidines as dipeptidyl peptidase inhibitors
DE10154689A1 (de) * 2001-11-09 2003-05-22 Probiodrug Ag Substituierte Aminoketonverbindungen
GB0125446D0 (en) 2001-10-23 2001-12-12 Ferring Bv Novel anti-diabetic agents
US6861440B2 (en) 2001-10-26 2005-03-01 Hoffmann-La Roche Inc. DPP IV inhibitors
CN1308311C (zh) 2002-02-13 2007-04-04 霍夫曼-拉罗奇有限公司 新型吡啶－和喹啉－衍生物
BR0307665A (pt) 2002-02-13 2005-01-04 Hoffmann La Roche Compostos, processo para a sua manufatura, composições farmacêuticas que compreendem os mesmos, método para o tratamento e/ou profilaxia de enfermidades associadas com dpp iv e utilização dos compostos
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
WO2004050022A2 (en) * 2002-12-04 2004-06-17 Merck & Co., Inc. Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US7687625B2 (en) * 2003-03-25 2010-03-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
ZA200508439B (en) 2003-05-05 2007-03-28 Probiodrug Ag Medical use of inhibitors of glutaminyl and glutamate cyclases
CN1784220B (zh) 2003-05-05 2011-08-03 前体生物药物股份公司 谷氨酰胺酰基和谷氨酸环化酶效应物的应用
KR20120035203A (ko) 2003-05-05 2012-04-13 프로비오드룩 아게 글루타미닐 및 글루타메이트 사이클라제의 이펙터의 용도
AU2004251829B2 (en) 2003-06-20 2009-12-17 F. Hoffmann-La Roche Ag Hexahydropyridoisoqinolines as DPP-IV inhibitors
KR100730867B1 (ko) 2003-06-20 2007-06-20 에프. 호프만-라 로슈 아게 Ｄｐｐ-ⅳ 억제제로서의 피리도[2,1-ａ]이소퀴놀린 유도체
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
CN1867560A (zh) * 2003-08-13 2006-11-22 武田药品工株式会社 4－嘧啶酮衍生物及其作为肽基肽酶抑制剂的用途
US7678909B1 (en) 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7205409B2 (en) 2003-09-04 2007-04-17 Abbott Laboratories Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
EP1697342A2 (en) * 2003-09-08 2006-09-06 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
JP2007505121A (ja) * 2003-09-08 2007-03-08 武田薬品工業株式会社 ジペプチジルぺプチダーゼ阻害剤
EP2289498A1 (en) 2003-10-15 2011-03-02 Probiodrug AG Use of inhibitors of glutaminyl clyclase
ZA200603165B (en) 2003-11-03 2007-07-25 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
KR20150028829A (ko) 2003-11-17 2015-03-16 노파르티스 아게 디펩티딜 펩티다제 ⅳ 억제제의 용도
ES2940341T3 (es) 2004-01-20 2023-05-05 Novartis Ag Formulación y proceso de compresión directa
KR101099206B1 (ko) 2004-02-05 2011-12-27 프로비오드룩 아게 신규한 글루타미닐 시클라제 저해제
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
CN102079743B (zh) * 2004-03-15 2020-08-25 武田药品工业株式会社 二肽基肽酶抑制剂
JP2008501714A (ja) * 2004-06-04 2008-01-24 武田薬品工業株式会社 ジペプチジルペプチダーゼインヒビター
WO2006019965A2 (en) 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
ATE553077T1 (de) 2004-07-23 2012-04-15 Nuada Llc Peptidaseinhibitoren
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
CN101090888A (zh) 2004-12-20 2007-12-19 霍夫曼-拉罗奇有限公司 4－氨基哌啶衍生物
US7411093B2 (en) 2004-12-20 2008-08-12 Hoffman-La Roche Inc. Aminocycloalkanes as DPP-IV inhibitors
WO2006068978A2 (en) 2004-12-21 2006-06-29 Takeda Pharmaceutial Company Limited Dipeptidyl peptidase inhibitors
BRPI0518651A2 (pt) 2004-12-24 2008-12-02 Dainippon Sumitomo Pharma composto, uma prà-droga do mesmo, ou um sal do composto ou prà-droga farmaceuticamente aceitÁvel, composiÇço farmacÊutica, inibidor de dipeptidil peptidase iv, uso de um composto, uma prà-droga do mesmo ou um sal do composto ou prà-droga farmaceuticamente aceitÁvel, e, mÉtodo para tratar diabetes
ZA200708179B (en) 2005-04-22 2009-12-30 Alantos Pharmaceuticals Holding Inc Dipeptidyl peptidase-IV inhibitors
JP2008545661A (ja) * 2005-05-19 2008-12-18 ジェネンテック・インコーポレーテッド 線維芽細胞活性化タンパク質阻害剤化合物および
EP1910317B1 (en) 2005-07-20 2013-07-03 Eli Lilly And Company 1-amino linked compounds
JP2009504599A (ja) * 2005-08-11 2009-02-05 エフ．ホフマン−ラ ロシュ アーゲー Ｄｐｐ−ｉｖ阻害剤を含有する医薬組成物
EP1760076A1 (en) * 2005-09-02 2007-03-07 Ferring B.V. FAP Inhibitors
DK1942898T4 (da) * 2005-09-14 2014-06-02 Takeda Pharmaceutical Dipeptidylpeptidase-inhibitorer til behandling af diabetes
MY159522A (en) * 2005-09-14 2017-01-13 Takeda Pharmaceuticals Co Administration of dipeptidyl peptidase inhibitors
KR101368988B1 (ko) 2005-09-16 2014-02-28 다케다 야쿠힌 고교 가부시키가이샤 디펩티딜 펩티다제 억제제
TW200745080A (en) * 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of tartrate salt of 2-[2-(3-(R)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6H-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor
TW200745079A (en) * 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
GB0525164D0 (en) 2005-12-09 2006-01-18 Xention Discovery Ltd Compounds
GB0526291D0 (en) 2005-12-23 2006-02-01 Prosidion Ltd Therapeutic method
JP2009531456A (ja) * 2006-03-28 2009-09-03 武田薬品工業株式会社 （ｒ）−３−アミノピペリジン二塩酸塩の調製
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2007123686A2 (en) * 2006-03-31 2007-11-01 Point Therapeutics, Inc. Dpp inhibitors and uses thereof
JP2009533393A (ja) 2006-04-12 2009-09-17 プロビオドルグ エージー 酵素阻害薬
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
CA2810839A1 (en) 2006-05-04 2007-11-15 Boehringer Ingelheim International Gmbh A polymorphic form of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(r)-amino-piperidin-1-yl)-xanthine
AU2007296556B2 (en) * 2006-09-13 2013-09-19 Takeda Pharmaceutical Company Limited Use of 2-6- (3-Amino-piperidin-1-yl) -3-methyl-2, 4-dioxo-3, 4-dihydro-2H-pyrimidin-1-ylmethyl-4-fluoro-benzonitrile
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
EP2091948B1 (en) 2006-11-30 2012-04-18 Probiodrug AG Novel inhibitors of glutaminyl cyclase
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
AU2008233548B2 (en) 2007-04-03 2011-12-01 Mitsubishi Tanabe Pharma Corporation Combined use of dipeptidyl peptidase IV inhibitor compound and sweetener
EP2865670B1 (en) 2007-04-18 2017-01-11 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
WO2009037719A1 (en) * 2007-09-21 2009-03-26 Lupin Limited Novel compounds as dipeptidyl peptidase iv (dpp iv) inhibitors
CL2008003653A1 (es) 2008-01-17 2010-03-05 Mitsubishi Tanabe Pharma Corp Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
CN101970402B (zh) * 2008-03-05 2013-12-18 财团法人国家卫生研究院 吡咯烷化合物
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
DE102008062136B4 (de) 2008-12-16 2012-05-03 Kamamed Ug Pharmazeutische Zusammensetzung auf Basis von Peptid aus Kamelmilch
BRPI0923121A2 (pt) 2008-12-23 2015-08-11 Boehringer Ingelheim Int Formas salinas de compostos orgânico
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
US8748457B2 (en) 2009-06-18 2014-06-10 Lupin Limited 2-amino-2- [8-(dimethyl carbamoyl)- 8-aza- bicyclo [3.2.1] oct-3-yl]-exo- ethanoyl derivatives as potent DPP-IV inhibitors
ES2548913T3 (es) 2009-09-11 2015-10-21 Probiodrug Ag Derivados heterocíclicos como inhibidores de glutaminil ciclasa
CN107115530A (zh) 2009-11-27 2017-09-01 勃林格殷格翰国际有限公司 基因型糖尿病患者利用dpp‑iv抑制剂例如利拉利汀的治疗
ES2586231T3 (es) 2010-03-03 2016-10-13 Probiodrug Ag Inhibidores de glutaminil ciclasa
AU2011226074B2 (en) 2010-03-10 2015-01-22 Vivoryon Therapeutics N.V. Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5)
EP2560953B1 (en) 2010-04-21 2016-01-06 Probiodrug AG Inhibitors of glutaminyl cyclase
KR101927068B1 (ko) 2010-05-05 2018-12-10 베링거 인겔하임 인터내셔날 게엠베하 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
CN102971005A (zh) 2010-06-24 2013-03-13 贝林格尔.英格海姆国际有限公司 糖尿病治疗
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
US8530670B2 (en) 2011-03-16 2013-09-10 Probiodrug Ag Inhibitors
EP3517539B1 (en) 2011-07-15 2022-12-14 Boehringer Ingelheim International GmbH Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EA021236B1 (ru) * 2012-10-03 2015-05-29 Дафот Энтерпраизес Лимитед Nα-АЦИЛЬНЫЕ ПРОИЗВОДНЫЕ АМИНОАЦИЛ-2-ЦИАНОПИРРОЛИДИНА - ИНГИБИТОРЫ ПРОЛИЛЭНДОПЕПТИДАЗЫ И ДИПЕПТИДИЛПЕПТИДАЗЫ-IV, ОБЛАДАЮЩИЕ ГИПОГЛИКЕМИЧЕСКИМ, ПРОТИВОГИПОКСИЧЕСКИМ, НЕЙРОПРОТЕКТОРНЫМ И УЛУЧШАЮЩИМ КОГНИТИВНЫЕ ФУНКЦИИ ДЕЙСТВИЕМ
JP6615109B2 (ja) 2014-02-28 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐ−４阻害薬の医学的使用
AU2016229982B2 (en) 2015-03-09 2020-06-18 Intekrin Therapeutics, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
CA3022202A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
WO2018162722A1 (en) 2017-03-09 2018-09-13 Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke Dpp-4 inhibitors for use in treating bone fractures
BR112019020485A2 (pt) 2017-04-03 2020-05-12 Coherus Biosciences, Inc. Agonista ppary para tratamento de paralisia supranuclear progressiva
DK3461819T3 (da) 2017-09-29 2020-08-10 Probiodrug Ag Inhibitorer af glutaminylcyklase
CN115368344A (zh) * 2022-08-22 2022-11-22 湖北科技学院 组氨酸类衍生物及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111785A0 (en) * 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
DE122010000020I1 (de) 1996-04-25 2010-07-08 Prosidion Ltd Verfahren zur Senkung des Blutglukosespiegels in Säugern
TW492957B (en) * 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
US6319902B1 (en) * 1997-08-22 2001-11-20 Shionogi & Co., Ltd. Peptide derivatives having thiazolyl-alanine residue
CO5150173A1 (es) * 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
SK12882001A3 (sk) * 1999-03-15 2002-04-04 Axys Pharmaceuticals, Inc. Zlúčeniny a prípravky ako proteinázové inhibítory
GB9906715D0 (en) 1999-03-23 1999-05-19 Ferring Bv Compositions for promoting growth
GB9906714D0 (en) * 1999-03-23 1999-05-19 Ferring Bv Compositions for improving fertility
US6172081B1 (en) 1999-06-24 2001-01-09 Novartis Ag Tetrahydroisoquinoline 3-carboxamide derivatives

Also Published As

Publication number Publication date
JP2003515585A (ja) 2003-05-07
CA2392713A1 (en) 2001-06-07
EE200200273A (et) 2003-06-16
SK7212002A3 (en) 2002-12-03
RU2265012C2 (ru) 2005-11-27
CN1402706A (zh) 2003-03-12
WO2001040180A3 (en) 2001-11-08
IL149359A (en) 2007-10-31
NO20022502D0 (no) 2002-05-27
AU1538401A (en) 2001-06-12
GB9928330D0 (en) 2000-01-26
CN1192020C (zh) 2005-03-09
WO2001040180A2 (en) 2001-06-07
CZ20021520A3 (cs) 2002-10-16
KR20020063185A (ko) 2002-08-01
BR0015788A (pt) 2002-07-16
EP1351932A2 (en) 2003-10-15
UA75341C2 (en) 2006-04-17
US6911467B2 (en) 2005-06-28
HRP20020421B1 (en) 2008-01-31
US20030096857A1 (en) 2003-05-22
MY131036A (en) 2007-07-31
AU781060B2 (en) 2005-05-05
HUP0203700A2 (hu) 2003-03-28
MXPA02005253A (es) 2002-11-07
PL355333A1 (en) 2004-04-19
HUP0203700A3 (en) 2004-01-28
IL149359A0 (en) 2002-11-10
US7169806B2 (en) 2007-01-30
US20050203031A1 (en) 2005-09-15
HRP20020421A2 (en) 2004-02-29
ZA200204283B (en) 2003-09-03

Similar Documents

Publication Publication Date Title
NO20022502L (no) Nye antidiabetiske midler
NO20014518D0 (no) Nye forbindelser
DK1202994T3 (da) Nye forbindelser
NO20033715D0 (no) Nye sammensetninger
DK1005356T3 (da) Nye antibakterielle midler
NO20021436L (no) Nye forbindelser
NO20000677L (no) Bronnhode
NO20020810L (no) Nye fenylpiperaziner
NO20001938D0 (no) Nye aryloksy-alkyl-dialkylaminer
NO20015383L (no) Nye forbindelser
DK1237857T3 (da) Nye Phenalkyloxyphenylderivater
NO20015074L (no) Nye sammensetninger
ID28483A (id) 2-(3,5-bis-trifluorometil-fenil)-metil-n-(6-morfolin-4-il-4-0-tolil-piridin-3-il)-isobutiramida
DE60003212T2 (de) Druckkopf
NO20022564D0 (no) Nye androgener
NO20030274L (no) Nye aryleten-sulfonamider
NO20022379D0 (no) Nye tiazolidinedionderivater som antidiabetiske midler
NO995945D0 (no) Nye forbindelser
NO20015374L (no) Nye forbindelser
NO20013601D0 (no) Nye morfolinobenzamidsalter
NO20014629D0 (no) Nye forbindelser
NO20016273L (no) Nye forbindelser
DE29900349U1 (de) Arbeitsvorrichtung
GT200000036A (es) Nuevas dihidropirimidinas
SE9901612D0 (sv) New use

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application